These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26968760)

  • 21. Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications.
    McKinnon JE; Maksimowicz-McKinnon K
    Transl Res; 2016 Jan; 167(1):46-60. PubMed ID: 26408802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural Immunomodulators 2018.
    Ortuño-Sahagún D; Rawat AKS; Zänker K
    J Immunol Res; 2019; 2019():4341698. PubMed ID: 31781677
    [No Abstract]   [Full Text] [Related]  

  • 23. Vaccines and vaccine adjuvants as biological response modifiers.
    Speil C; Rzepka R
    Infect Dis Clin North Am; 2011 Dec; 25(4):755-72. PubMed ID: 22054754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Off-label use of biological therapies in systemic diseases].
    Hachulla E
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
    [No Abstract]   [Full Text] [Related]  

  • 25. Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review.
    Wainwright CL; Teixeira MM; Adelson DL; Buenz EJ; David B; Glaser KB; Harata-Lee Y; Howes MR; Izzo AA; Maffia P; Mayer AM; Mazars C; Newman DJ; Nic Lughadha E; Pimenta AM; Parra JA; Qu Z; Shen H; Spedding M; Wolfender JL
    Pharmacol Res; 2022 Mar; 177():106076. PubMed ID: 35074524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future immunotherapy targets in autoimmune neurology.
    Hu MY; Stathopoulos P; O'connor KC; Pittock SJ; Nowak RJ
    Handb Clin Neurol; 2016; 133():511-36. PubMed ID: 27112694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.
    van Eden W; Lisse J; Prakken B; Albani S
    Drug Discov Today; 2010 Jan; 15(1-2):71-7. PubMed ID: 19162218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revisiting eukaryotic anti-infective biotherapeutics.
    Rishi P; Singh AP; Arora S; Garg N; Kaur IP
    Crit Rev Microbiol; 2014 Nov; 40(4):281-92. PubMed ID: 23317462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial: Strategies in the drug discovery and development for leishmaniasis: immunomodulators, natural products, synthetic compounds, and drug repositioning.
    de Almeida TF; Cunha-Junior EF; Wanderley JLM; Pacheco JDS; Pinto-da-Silva LH; Andrade-Neto VV; Chaves SP
    Front Cell Infect Microbiol; 2024; 14():1384244. PubMed ID: 38544526
    [No Abstract]   [Full Text] [Related]  

  • 30. Schistosome Infection and Schistosome-Derived Products as Modulators for the Prevention and Alleviation of Immunological Disorders.
    Mu Y; McManus DP; Hou N; Cai P
    Front Immunol; 2021; 12():619776. PubMed ID: 33692793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microalgae with Immunomodulatory Activities.
    Riccio G; Lauritano C
    Mar Drugs; 2019 Dec; 18(1):. PubMed ID: 31861368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural products that reduce rotavirus infectivity identified by a cell-based moderate-throughput screening assay.
    Shaneyfelt ME; Burke AD; Graff JW; Jutila MA; Hardy ME
    Virol J; 2006 Sep; 3():68. PubMed ID: 16948846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial peptides: an alternative for innovative medicines?
    da Costa JP; Cova M; Ferreira R; Vitorino R
    Appl Microbiol Biotechnol; 2015 Mar; 99(5):2023-40. PubMed ID: 25586583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
    Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
    Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural products: an evolving role in future drug discovery.
    Mishra BB; Tiwari VK
    Eur J Med Chem; 2011 Oct; 46(10):4769-807. PubMed ID: 21889825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. beta-Glycosphingolipids as immune modulators.
    Adar T; Ilan Y
    J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy and vaccination against infectious diseases.
    Ebbers M; Hemmer CJ; Müller-Hilke B; Reisinger EC
    Wien Klin Wochenschr; 2021 Jul; 133(13-14):714-720. PubMed ID: 33326055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.